Title: John Staniforth: Innovator in Pharmaceutical Compositions
Introduction
John Staniforth is a notable inventor based in Great Britain. He has made significant contributions to the field of pharmaceutical formulations, particularly in enhancing dosing efficiency for respiratory diseases. Although he currently holds no patents, his work has the potential to impact the medical community significantly.
Latest Patents
Staniforth's latest inventions include "Devices And Pharmaceutical Compositions For Enhancing Dosing Efficiency." This invention focuses on improving the dosing efficiency of apomorphine dry powder formulations administered through pulmonary inhalation. The formulation consists of active particles mixed with carrier particles, both of which are treated with a force control agent to optimize delivery. Another notable invention is "The Treatment Of Respiratory Diseases," which involves a pharmaceutical composition for pulmonary delivery that includes glycopyrrolate in a controlled release formulation. This formulation is designed to exert its pharmacological effect for over 12 hours upon administration.
Career Highlights
Throughout his career, John Staniforth has worked with several companies, including Arakis Ltd. and Vectura GmbH. His experience in these organizations has allowed him to develop innovative solutions in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Robin Mark Bannister and Andrew John Richards. Their collaborative efforts have contributed to advancements in pharmaceutical technologies.
Conclusion
John Staniforth is an innovative inventor whose work in pharmaceutical compositions has the potential to enhance treatment options for respiratory diseases. His contributions, although not yet patented, reflect a commitment to improving healthcare through scientific advancements.